Brothers with Smith-Lemli-Opitz syndrome

J Pediatr Health Care. 2015 Jan-Feb;29(1):97-103. doi: 10.1016/j.pedhc.2014.04.006. Epub 2014 Jun 20.

Abstract

Abnormal cholesterol metabolism is the cause of SLOS, with low cholesterol levels and elevated levels of cholesterol precursors thought to contribute to the clinical findings in this syndrome. Management of SLOS involves early intervention with appropriate therapies for identified disabilities, genetic counseling for families, nutritional consultations, educational interventions, and behavioral management. Although no randomized dietary studies have been conducted, cholesterol supplementation continues to be a common recommendation for persons with SLOS, because it may result in clinical improvement and has few adverse effects (Nowaczyk, 2013). Even with early detection and treatment (e.g., sibling B in this case report), persons with SLOS often have significant behavioral issues and cognitive and developmental delays that require a team approach by parents, educators, specialists, and primary care providers.

Keywords: Inherited metabolic error; autosomal recessive; cholesterol; developmental delays.

Publication types

  • Case Reports

MeSH terms

  • Abnormalities, Multiple / diagnosis
  • Child, Preschool
  • Humans
  • Infant, Newborn
  • Male
  • Microcephaly / diagnosis
  • Oxidoreductases Acting on CH-CH Group Donors / blood
  • Oxidoreductases Acting on CH-CH Group Donors / genetics
  • Siblings
  • Smith-Lemli-Opitz Syndrome / diagnosis*
  • Smith-Lemli-Opitz Syndrome / genetics
  • Smith-Lemli-Opitz Syndrome / pathology
  • Smith-Lemli-Opitz Syndrome / therapy

Substances

  • Oxidoreductases Acting on CH-CH Group Donors
  • 7-dehydrocholesterol reductase